Literature DB >> 11855547

Colorectal cancer risk: the impact of evidence of a field effect of carcinogenesis on blinded diagnosis using an anti-adenoma antibody test performed on colonoscopic effluent.

Martin Tobi1, Shivkumar Prabhu, Rhonda E Gage, Tashia Orr, Michael J Lawson.   

Abstract

To better define high-risk populations for colorectal cancer screening, we used anti-adenoma antibody Adnab-9, comparing colonic effluent and tissue field effects from 45 high-risk and 11 control patients. We included Adnab-9 binding at the tissue level to elucidate the impact of a field effect of carcinogenesis contributing to the outcome of the effluent binding test. In high-risk patients, 64% of the left-sided effluent samples were positive (P < 0.002); 67% showed a field effect (P < 0.006); 82% of combined tests were positive (P < 0.001), as compared to 9%, 18%, and 27% respectively, of controls. Adnab-9 binding correlates with increased colorectal cancer risk associated with a field effect of carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855547     DOI: 10.1023/a:1013713920805

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Detection of carcinoembryonic antigen in colonic effluent by specific anti-CEA monoclonal antibodies.

Authors:  M Tobi; D O'Kieffe; N Trujillo; L E Nochomovitz; W M Steinberg
Journal:  Cancer Lett       Date:  1992-10-30       Impact factor: 8.679

2.  Colorectal cancer screening: clinical guidelines and rationale.

Authors:  S J Winawer; R H Fletcher; L Miller; F Godlee; M H Stolar; C D Mulrow; S H Woolf; S N Glick; T G Ganiats; J H Bond; L Rosen; J G Zapka; S J Olsen; F M Giardiello; J E Sisk; R Van Antwerp; C Brown-Davis; D A Marciniak; R J Mayer
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

3.  Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

Authors:  D A Ahlquist; J E Skoletsky; K A Boynton; J J Harrington; D W Mahoney; W E Pierceall; S N Thibodeau; A P Shuber
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

4.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.

Authors:  D Sidransky; T Tokino; S R Hamilton; K W Kinzler; B Levin; P Frost; B Vogelstein
Journal:  Science       Date:  1992-04-03       Impact factor: 47.728

Review 5.  Polyps as biomarkers for colorectal neoplasia.

Authors:  M Tobi
Journal:  Front Biosci       Date:  1999-03-15

6.  Mucosal origin and shedding of an early colonic tumor marker defined by Adnab-9 monoclonal antibody.

Authors:  M Tobi; Y Elitsur; M P Moyer; A Halline; M Deutsch; L Nochomovitz; G D Luk
Journal:  Scand J Gastroenterol       Date:  1993-12       Impact factor: 2.423

7.  Increased expression of a putative adenoma-associated antigen in pre-colonoscopic effluent of patients with colorectal cancer.

Authors:  M Tobi; E Darmon; T Phillips; T Heller; P Rozen; L Nochomovitz; W Steinberg
Journal:  Cancer Lett       Date:  1990-05-15       Impact factor: 8.679

8.  Adenoma-derived antibody, Adnab-9 recognizes a membrane-bound glycoprotein in colonic tissue and effluent material from patients with colorectal neoplasia.

Authors:  M Tobi; B Maliakkal; I Zitron; M Alousi; R Goo; L Nochomovitz; G Luk
Journal:  Cancer Lett       Date:  1992-10-30       Impact factor: 8.679

9.  Oral colon lavage solutions containing polyethylene glycol may interfere with ELISA detection of tumor-associated antigens in colonic effluent.

Authors:  M Tobi; E Darmon; P Rozen; N Epstein; F Konikoff; J Stadler; N Harpaz; A Fink; Z Bentwich; B Maliakkal
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

10.  Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma.

Authors:  M Tobi; F C Luo; Z Ronai
Journal:  J Natl Cancer Inst       Date:  1994-07-06       Impact factor: 13.506

View more
  6 in total

Review 1.  Cecal stampede: the headlong rush for screening colonoscopy: a position paper.

Authors:  Michael J Lawson; Martin Tobi
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

2.  Differential labeling by monoclonal antibodies Adnab-9 and anti-alpha-defensin 5 based on the distribution and adenomatous tissue content of colonic polyps.

Authors:  Nadeem Ullah; Kashif Qureshi; Violeta Yordanova; James Hatfield; Paula Sochacki; Michael Lawson; Martin Tobi
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 3.  Rectal effluent as a research tool.

Authors:  Jana M Rocker; Jack A DiPalma; Lewis K Pannell
Journal:  Dig Dis Sci       Date:  2014-09-02       Impact factor: 3.199

4.  Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma.

Authors:  Martin Tobi; Mijin Kim; Douglas H Weinstein; Mary Ann Rambus; James Hatfield; N Volkan Adsay; Edi Levi; Douglas Evans; Michael J Lawson; Suzanne Fligiel
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

5.  An anti-adenoma antibody, Adnab-9, may reflect the risk for neoplastic progression in familial hamartomatous polyposis syndromes.

Authors:  Martin Tobi; Michael Kam; Nadeem Ullah; Kashif Qureshi; Violeta Yordanova; James Hatfield; Suzanne E G Fligiel; Paula Sochacki; Thomas McGarrity; Carolyn Cole; Michael Lawson; Russell Jacoby
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

6.  The use of early and midpoint adenoma-carcinoma sequence biomarkers in prediction of neoplastic progression in patients with a history of colorectal neoplasia.

Authors:  Hassan Albataineh; Violeta Yordanova; Jessica Bowman; Weili Zhou; James Hatfield; Michael J Lawson; Paula Sochacki; Martin Tobi
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.